Newer progestogens
Tóm tắt
Từ khóa
Tài liệu tham khảo
Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002; 9: 6–15.
Kumar N, Koide SS, Tsong Y-Y, et al. Nestorone: a progestin with a unique pharmacological profile. Steroids 2000; 65: 629–636.
Oettel M, Holz C. Hybrid progestins: the example of dienogest. In: Sitruk-Ware R, Mishell DR (eds), Progestins and antiprogestins in clinical practice. New York, NY: Marcel Dekker, 2000; 163–178.
Zimmermann T, Dietrich H, Wisser K-H, et al. The efficacy and tolerability of Valette®: a postmarketing surveillance study. Eur J Contracept Reprod Health Care 1999; 4: 155–164.
Moore C, Luderschmidt C, Moltz L, et al. Antiandrogenic properties of the dienogest-containing oral contraceptive Valette®. Med Actual 1999; 35(Suppl. C): 69–78.
Oelkers W, Berger V, Bolik A. Dihydrospirenone, a new progestogen with antimineralocortcoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73: 837–842.
Oelkers W, Helmerhorst FM, Wuttke W, et al. Effect of an oral contraceptive containing drospirenone on the renin-angiotensinaldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204–213.
Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816–1821.
Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5: 25–34.
Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5: 124–134.
van Vloten W, van Haselen CW, van Zuuren EJ, et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002; 69(Suppl.4): 2–15.
Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001; 10: 561–569.
Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone: effect on premenstrual symptoms. J Reprod Med 2002; 47: 14–22.
Sitruk-Ware R, Sundaram K. Pharmacology of new progestogens: the 19-norprogesterone derivatives. In: Sitruk-Ware R, Mishell DR (eds), Progestins and antiprogestins in clinical practice. New York, NY: Marcel Dekker, 2000; 153–161.
Barbosa I, Coutinho E, Hirsch C, et al. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years. Fertil Steril 1996; 65: 724–729.
Coutinho EM, de Souza JC, Athayde C, et al. Multicenter clinical trial on the efficacy and acceptability of a single contraceptive implant of nomegestrol acetate, Uniplant. Contraception 1996; 53: 121–125.
Brache V, Faundes A, Alvarez F, et al. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception 2002; 65: 63–74.
Urbancsek J. An integrated analysis of nonmenstrual adverse events with Implanon. Contraception 1998; 58: 109S–115S.
Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomised comparative trial. Contraception 1994; 49: 56–72.
Barbosa I, Coutinho E, Athayde C, et al. The effects of nomegestrol acetate subdermal implant (Uniplant) on carbohydrate metabolism, serum lipoproteins and on hepatic function in women. Contraception 1995; 52: 111–114.
Barbosa I, Coutinho E, Athayde C, et al. Androgen levels in women using a singleimplantof nomegestrol acetate. Contraception 1996;53: 37–40.
Dorflinger LJ. Metabolic effects of implantable steroid contraceptives for women. Contraception 2002; 65: 47–62.
Sivin I, Moo-Young A. Recent developments in contraceptive implants at the Population Council. Contraception 2002; 65: 113–119.
Fraser IS, Weisberg E, Minehan E, et al. A detailed analysis of menstrual blood loss in women using Norplant® and Nestorone® progestogen-only contraceptive implants or vaginal rings. Contraception 2000; 61: 241–251.
Brache V, Mishell DR, Lahteenmaki P, et al. Ovarian function during use of vaginal rings delivering three different doses of Nestorone®. Contraception 2001; 63: 257–261.
Laurikka-Routti M, Haukkamaa M, Heikinheimo O. A contraceptive vaginal ring releasing ethinylestradiol and progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry. Contraception 1990; 42: 111–120.
Haukkamaa M, Laurikka-Routti M, Heikinheimo O. Transdermal absorption of the progestin ST-1435: therapeutic serum steroid concentrations and high excretion of the steroid in saliva. Contraception 1991; 44: 269–276.
Zhang Z, Lundeen SG, Zhu Y, et al. In vitro characterization of trimegestone: a new potent and selective progestin. Steroids 2000;65: 637–643.
Philibert D, Bouchoux F, Degryse M, et al. The pharmacological profile of a novel norpregnane progestin (trimegestone). Gynecol Endocrinol 1999; 13: 316–326.
Coney P, Washenik K, Langley RGB, et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001; 63: 297–302.
Levell MJ, Cawood ML, Burke B, et al. Acne is not associated with abnormal plasma androgens. Br J Dermatol 1989; 120: 649–654.
Pye RJ, Meyrick G, Pye MJ, et al. Effect of oral contraceptives on sebum excretion rate. BMJ 1977; 2: 1581–1582.